Abstract
Objective To observe the efficacy of intravitreal injection of Ranibizumab for the treatment of chronic central serous chorioretinopathy(CSC). Methods Prospective cohort study. Forty-eight eyes of 45 cases with chronic CSC from Dec. 2015 to Jan. 2017 were recruited in this study. All cases received intravitreal injection of Ranibizumab. The visual acuities were recorded before and 2, 4, 8 weeks after injection. Subfoveal choroidal thickness (SFCT) and central macular choroidal thickness (CMCT) of 1 500 μm superior, inferior, nasal and temporal to the fovea were measured by OCT. Results The visual acuity (Log MAR) was 0.33±0.08, 0.24±0.19, 0.18±0.17 and 0.16±0.20 before and 2, 4, 8 weeks after injection. The visual acuities at different time point after injection were better than that before injection. The difference was significant between before and after injection(F=18.50, P=0.00). SFCT before injection was (443.63 ±98.32) μm, which decreased significantly to (393.55±97.66) μm, (379.53±93.55) μm, (388.30±96.52) μm at 2, 4, 8 weeks after treatment respectively(F=105.54, P<0.01). The changing trends of choroidal thickness measuring points were similar to the SFCT. Conclusion Intravitreal injection of Ranibizumab for the treatment of chronic CSC can reduce posterior choroidal thickness and improve vision. Key words: Chorioretinopathy, serous, central, chronic; Ranibizumab, intravitreal injection; Choroidal thickness
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Ocular Trauma and Occupational Eye Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
